Necitumumab pharmacokinetics is characterized by target-mediated drug disposition, with a volume of distribution approximate to blood volume and a half-life of 2 weeks.

No age, sex, race, or concomitant medication factors were found influential, while weight explained a limited percentage of variability in distribution and elimination.

Simulations from the final model indicated that a only minor reduction in patient drug exposure variability would be achieved by weight- or body surface area-based dosing.